Intralytix Acquires Site for New Headquarters
Baltimore, Maryland U.S.A. - May 11, 2018. Intralytix, Inc., announced today that it has closed on the acquisition of a 33,000 sq. ft. building in Columbia, Maryland. The facility, located in the Columbia Gateway Community, will serve as the Company's new headquarters. Plans are underway to house expanded research and laboratory space, executive offices, and substantially increased manufacturing capacity.
"This acquisition marks an important milestone in Intralytix's history," remarked Dr. Alexander Sulakvelidze, the Company's Executive Vice President and Chief Scientific Officer. "This expansion further solidifies Intralytix's position as the leading phage company in the world and creates significant opportunities for future growth. This is especially timely now as the enthusiasm for bacteriophage-based products for controlling and treating bacterial pathogens - including multidrug resistant pathogens - is growing worldwide" Dr. Sulakvelidze noted. John Woloszyn, the Company's President, estimates that completion of the necessary improvements should take approximately 9 to 12 months.
Intralytix, Inc. is a privately-held company currently headquartered in downtown Baltimore, Maryland. The company is the world's leader in bacteriophage technology and was the first company in the world to receive FDA-approval for a phage-based product for food safety applications. Intralytix currently has the world's largest portfolio of FDA-approved phage-based food safety products on commercial markets. The company holds several bacteriophage technology-related patents, including two U.S. patents (and additional patents pending) on the use of bacteriophages for fine tuning human or animal microbiome (US 7,459,272 B2 and US 8,003,323 B2).
To learn more about Intralytix, Inc. or its products please visit www.intralytix.com. Most recently, Intralytix announced receipt of regulatory clearance from the FDA to commence clinical studies of a new, phage-based formulation designed to target inflammatory bowel disease. These studies are scheduled to commence at Mt. Sinai Hospital later this year.
For more information, contact Dr. Alexander Sulakvelidze at +1 410-625-2533 or firstname.lastname@example.org; or John Woloszyn at +1 410-625-3813 or email@example.com.
May 11, 2018